Unlock Exclusive Discounts & Flash Sales! Click Here to Join the Deals on Every Wednesday!

In Vivo Pharmacodynamic Evaluation of COV504 Cell Line Based Ovary Cancer (CAT#: STEM-AE-0096-LGZ)

Introduction

Ovary cancer is a kind of malignant tumor of ovary. It refers to malignant tumors growing on the ovary. 90% to 95% of these tumors are primary cancers of the ovary, and 5% to 10% are metastases of primary cancers from other parts of the ovary. Early diagnosis is difficult because of the lack of early symptoms of ovary cancer, the lack of specificity of symptoms, and the limited effectiveness of screening. Sixty to seventy percent of ovary cancer is late at diagnosis, and the outcome of late cases is poor. Thus, although the incidence of ovary cancer is lower than that of cervical cancer and endometrial cancer, which rank third among gynecological malignancies, the mortality rate is higher than that of cervical cancer and endometrial cancer combined.




Principle

In vivo activity is the gold standard for the evaluation of drug biological activity, and it is the first verification of non-human comprehensive activity. In vivo pharmacodynamic evaluation plays a decisive role in the confirmation of candidate molecules and the screening of clinical target indications, and is an indispensable link in the development of new drugs. We provide a variety of disease animal models including inflammation, immunity, metabolism, etc., to meet the needs of different new drug research and development projects of customers, and accept customized services.
In vivo pharmacodynamic evaluation, as the basic research of new drugs, is carried out on animals. It is to verify the effect of drugs with the comprehensive participation of a number of other factors, and to understand the effect of drugs on a certain part of the body by comparing and analyzing the animal signs, in vitro organs, blood components, histone expression and tissue changes before and after drug administration.

Applications

Ovary Cancer

Procedure

1. Disease model construction.
2. Mice dosing.
3. Efficacy monitoring.
4. Biochemical detection of tissue samples.

Materials

• Sample Type: liquid or powder

Notes

Oncology efficacy Service package:
In vivo syngeneic model
In vivo CDX model
In vivo PBMC humanized model
In vivo transgenic mouse model
In vivo orthotropic or Metastasis tumor model